Clinical Trials Logo

Filter by:
NCT ID: NCT04845295 Completed - Hypertrophy Clinical Trials

Resistance Training Effects on Muscle Morphological, Mechanical and Contractile Properties

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The aim of the research project is to investigate the influence of resistance-training prescription (repetition duration, time under tension and training volume) and sex have on morpho-functional adaptations of upper and lower-body skeletal muscles. Twenty-four male and female university students were randomly assigned to one of two experimental groups, based on the repetition duration : "fast" group (with 1 second for eccentric and concentric phase) and "slow" group with prolonged duration of eccentric contraction (4 seconds for eccentric and 1 second concentric phase). At baseline and final measurement, cross-section area, one-repetition maximum and tensiomyography parameters (contraction time - Tc and radial displacement - Dm) of elbow flexors (biceps brachii) and knee extensors (4 quadriceps muscles) were evaluated.

NCT ID: NCT04824092 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Start date: April 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

NCT ID: NCT04801914 Recruiting - Clinical trials for Matrix Metalloproteinase

Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia Before and After PTBD

Start date: December 11, 2020
Study type: Observational

The purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.

NCT ID: NCT04786509 Completed - Clinical trials for ECG Electrode Site Reaction

Wireless ECG Body Sensor During Field Testing

Start date: June 1, 2018
Study type: Observational

Wireless body ECG sensor is a feasible solution for reliable and accurate long-term heart rhythm monitoring. However, there were no studies that delt with usability of this sensor in field testing. Accordingly, the aim of the study is to evaluate the quality of ECG signal measured with wearable wireless ECG body-sensor when used in field test settings and to determine how different types of sensors' fixation affect quality of the ECG signal during submaximal and maximal running settings. Twenty-three participants, 10 females and 13 males, were included in the study (20.56±1.19 years). All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests. Test outcomes were compared applying Student t-test for dependent variables, or non-parametric Wilcoxon test, depending on the results of normality test.

NCT ID: NCT04777357 Not yet recruiting - Depression Clinical Trials

A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder

Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population. Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide. Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT04773223 Recruiting - Clinical trials for Juxtarenal Aortic Aneurysm

Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment

Start date: January 1, 2011
Study type: Observational

Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA. Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities. Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.

NCT ID: NCT04764188 Not yet recruiting - NSCLC Clinical Trials

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Start date: April 2, 2021
Study type: Observational

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

NCT ID: NCT04744558 Completed - Ketogenic Dieting Clinical Trials

Low Carbohydrate High Fat Ketogenic vs. Non-ketogenic Diet

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The aim of this paper was to investigate and compare the effects of two iso-energetic hypo-caloric ketogenic hyper-ketonemic and non-ketogenic low carbohydrate high fat high cholesterol diets on body-composition, muscle strength and hormonal profile in experienced resistance-trained middle-aged men. Twenty non-competitive experienced resistance-trained middle-aged men were on the supervised calorie maintenance western diet and resistance-training regimen for 4 weeks and then divided into ketogenic and non-ketogenic groups for 8 weeks period. Keto bodies (β-hydroxybutyrate) levels were measured weekly, testosterone and insulin biweekly, strength and body-composition monthly, lipid profile and blood sugar level at the beginning and at the end of the study.

NCT ID: NCT04735926 Recruiting - Clinical trials for Vitamin D Deficiency

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

Start date: December 23, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomised, double-blind, double-dummy, multicentre, dose-ranging clinical trial in subjects with vitamin D deficiency or insufficiency. Its general objective is to determine the efficacy and safety of different doses of calcifediol soft gelatin capsules (SGCs) compared to placebo.

NCT ID: NCT04727073 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Spironolactone In The Treatment of Heart Failure

Start date: November 1, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of recurrent heart failure hospitalizations and cardiovascular mortality.